drugset / Trial / NCT02814097
A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction
Phase 2
Completed
46 enrolled
Stealth BioTherapeutics Inc.
Charite University, Berlin, Germany · collabSCIRENT Clinical Research and Science d.o.o. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a multi-center, randomized, double-blind, placebo-controlled study in subjects with stable heart failure with preserved ejection fraction (HFpEF) to evaluate the effects of 4 weeks treatment with subcutaneous MTP-131 (elampretide) on left ventricular function.
Timeline
- Start
- 2016-09-02
- Primary completion
- 2017-05-04
- Completion
- 2017-06-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elamipretide | Peptide | 40 mg | Subcutaneous |